Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disulfiram in Inherited Retinal Degeneration
NCT05626920Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- May 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in inherited retinal degeneration (IRD) comparing Placebo with Disulfiram (2 arms). Primary endpoint: Retinal sensitivity at 1 year. Started May 2026; status: recruiting.
02
Drugs
disulfiram
03
Conditions
inherited retinal degeneration (IRD)
Beyond the preview
Go deeper on NCT05626920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05626920.